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Abstract
Schinzel-Giedion syndrome (SGS) is a rare developmental disorder characterized by multi-
ple malformations, severe neurological alterations and increased risk of malignancy. SGS is
caused by de novo germline mutations clustering to a 12bp hotspot in exon 4 of SETBP1.
Mutations in this hotspot disrupt a degron, a signal for the regulation of protein degradation,
and lead to the accumulation of SETBP1 protein. Overlapping SETBP1 hotspot mutations
have been observed recurrently as somatic events in leukemia. We collected clinical infor-
mation of 47 SGS patients (including 26 novel cases) with germline SETBP1 mutations and
of four individuals with a milder phenotype caused by de novo germline mutations adjacent
to the SETBP1 hotspot. Different mutations within and around the SETBP1 hotspot have
varying effects on SETBP1 stability and protein levels in vitro and in in silico modeling. Sub-
stitutions in SETBP1 residue I871 result in a weak increase in protein levels and mutations
affecting this residue are significantly more frequent in SGS than in leukemia. On the other
hand, substitutions in residue D868 lead to the largest increase in protein levels. Individuals
with germline mutations affecting D868 have enhanced cell proliferation in vitro and higher
incidence of cancer compared to patients with other germline SETBP1 mutations. Our find-
ings substantiate that, despite their overlap, somatic SETBP1 mutations driving malignancy
are more disruptive to the degron than germline SETBP1 mutations causing SGS. Addition-
ally, this suggests that the functional threshold for the development of cancer driven by the
disruption of the SETBP1 degron is higher than for the alteration in prenatal development in
SGS. Drawing on previous studies of somatic SETBP1 mutations in leukemia, our results
reveal a genotype-phenotype correlation in germline SETBP1 mutations spanning a molec-
ular, cellular and clinical phenotype.
Author summary
Several Mendelian disorders are caused by germline de novo mutations in genes in
which somatic mutations have been implicated as cancer driver mutations. Germline de
novo mutations in a hotspot of SETBP1 cause Schinzel-Giedion syndrome (SGS), a rare
developmental disorder characterized by neurological alterations, malformations and
increased cancer risk. Overlapping somatic SETBP1 mutations have been identified
recurrently in myeloid leukemia. In this study, we characterize at the molecular and clin-
ical level the largest cohort yet of individuals with SGS. We analyze the distribution and
magnitude of effect of germline and somatic SETBP1 mutations in SGS and leukemia,
respectively. SETBP1 mutations with weak effect are almost exclusively germline events,
while strongly activating SETBP1 mutations occur both in SGS and leukemia. Strikingly,
most cancer cases in SGS are observed in patients with strongly activating germline
SETBP1 mutations. Our findings support a genotype-phenotype correlation for SGS and
Overlapping germline and somatic mutations in SETBP1
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suggest the existence of a functional threshold required to drive malignancy both for
germline and somatic SETBP1 mutations. This finding could be extrapolated to muta-
tions in other genes implicated in developmental disorders and cancer, showing that the
fields of cancer and developmental genetics can learn from the other discipline to gain
insight into their own subject.
Introduction
Schinzel-Giedion syndrome (SGS; OMIM 269150) is a rare developmental disorder character-
ized by multiple malformations including midface hypoplasia, cardiac defects, hydronephrosis
and skeletal abnormalities [1–3]. This clinically recognizable syndrome was the first dominant
disorder for which the underlying genetic cause was identified by whole exome sequencing
[4]. In 12 of 13 unrelated individuals with this disorder, we identified germline de novo muta-
tions in SETBP1 clustering to a hotspot of 12 base pairs coding for residues 868 to 871 of the
SETBP1 protein [4]. Interestingly, shortly after the identification of germline de novo muta-
tions in SETBP1 as the cause of SGS, overlapping somatic mutations in SETBP1 were reported
in several types of myeloid malignancies [5–7]. This dual role in cancer and development is
not unique to SETBP1; a growing number of genes in which germline mutations cause devel-
opmental disorders, such as HRAS, ASXL1, EZH2 and FGFR2, are also known to harbor over-
lapping somatic mutations which drive the development of cancer [8]. This genetic overlap is
not entirely unexpected; higher rates of childhood cancer have been identified in individuals
with birth defects and vice versa [9–11], a finding which is thought to be the consequence of
abnormalities in molecular pathways shared between embryogenesis and cancer development
[12,13].
The precise function of SETBP1, which encodes the SET-binding protein 1 (OMIM
611060), is yet to be discovered and, as a result, the molecular consequences of SETBP1
mutations remain largely unknown. However, the clustering of all germline SETBP1 muta-
tions identified in SGS to a single region and their overlap with the somatic events identified
in myeloid malignancies support a gain-of-function effect on the SETBP1 protein. This
recurrently mutated region of the protein is highly conserved and has been identified as
a degron signal targeted by the SCF-βTrCP1 E3 ligase [5]. A degron is a peptide sequence
that is recognized and bound by a component of the ubiquitin-proteasome pathway, thereby
initiating degradation of the protein by ubiquitination [14]. As a result, mutations localizing
to the degron in SETBP1 disrupt binding by the βTrCP1 E3 ligase, increase protein stability
by interfering with ubiquitination [15] and ultimately lead to accumulation of SETBP1
protein in cells [5]. While the molecular consequences of germline SETBP1 mutations are
poorly understood, somatic mutations disrupting the SETBP1 degron lead to increased pro-
liferation in myeloid progenitors [7], possibly mediated by effects on its interaction partner
SET, phosphorylation of PP2A and transcriptional activation of HOXA9 and HOXA10
[5,16,17].
Additional clinical and functional investigation is warranted to gain more understanding
about the molecular mechanisms of SGS. Here we present the clinical characterization of the
largest cohort of individuals with genetically confirmed SGS and establish genotype-phenotype
correlations for SGS. Given the occurrence of overlapping germline and somatic SETBP1
mutations, we compare the mutations in SGS and leukemia to identify genetic and functional
differences between SETBP1 mutations in both conditions.
Overlapping germline and somatic mutations in SETBP1
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Results
Clinical features of SGS
Classic SGS is caused by mutations within four residues of the SETBP1 degron (D868, S869,
G870 and I871, Fig 1A and 1B), constituting the critical consensus sequence of the degradation
signal [18] (from here on, referred to as the canonical degron). Since the initial description of
12 mutation-positive cases [4], we have gathered clinical details of 26 additional individuals
with SGS genetically confirmed by the presence of de novo mutations in SETBP1 (see Table 1
and S1 Table). In addition, we present three patients with a milder phenotype variably overlap-
ping with SGS and secondary to novel mutations in SETBP1 affecting highly conserved resi-
dues in close proximity to the canonical degron (current cases 27–29, with mutations in
residues E862, S867 and T873 shown in green in Fig 1B). We report on the clinical features
observed in our cohort in addition to previously published mutation-positive cases to further
delineate this disorder (n = 51 individuals).
Dysmorphic facial features. All individuals with SGS have characteristic facial features
that are easily recognizable (Fig 1C and S1 Fig). Typically, SGS patients have large fontanelles
(n = 37/41), a prominent forehead (n = 41/44), bitemporal narrowing (n = 32/36), shallow
orbits or prominent eyes (n = 36/38), hypertelorism (n = 36/42) a retracted and shortened
midface (n = 45/45) and full cheeks, leading to a facial frontal silhouette in the shape of a num-
ber eight [19]. Additionally, most patients have a deep groove under the eyes (n = 38/39),
upslanting palpebral fissures (n = 21/26) and a short nose with a bulbous nasal tip (n = 43/44).
Some individuals may present with less recognizable facial features in the first weeks after
birth and after the age of 18 months. In those cases, additional diagnostic clues that may facili-
tate the diagnosis include the abnormal shape of the ears (n = 38/39). Classically, the ears of
individuals with SGS are low-set and posteriorly rotated with anteriorly angulated lobules giv-
ing rise to a question mark shape (Fig 1D). In individuals who do not have the typical lobules,
the majority does have folded helices and prominent anti-helices. About half of the patients
show a large mouth (n = 17/33) with an everted lower lip and a protruding tongue (n = 18/38).
In addition, they may present with micrognathia (n = 29/30) and a philtrum groove. Hypertri-
chosis was identified in two thirds of the patients (n = 26/37), facial hemangioma in eight of 33
cases and a short neck in 30 of 33 cases.
Skeletal features. As molecular testing for SETBP1 mutations has become available, the
extent of diagnostic radiologic evaluations has diminished and, therefore, has not been per-
formed in all patients within this cohort (data were available for 31 cases). Skeletal characteris-
tics present in over 75% of these patients included a sclerotic base of the skull (n = 19/23) with
wide occipital synchondrosis (n = 18/23), widening of ribs (n = 27/31), short pubic rami, wide
pubic symphysis (n = 18/20) and hypoplastic distal phalanges in hands and feet (n = 21/25). In
case 22, the synchondrosis had closed completely in a later radiologic examination. Post-axial
polydactyly was noted in only 11% of patients (n = 4/38). Retrospective study of photographs
of the hands of individuals with SGS shows that a typical posture with clenched fingers is com-
mon (Fig 1E and 1F).
Neurologic features. Microcephaly was observed in approximately two thirds of the indi-
viduals with SGS (n = 29/39). The occipitofrontal circumference in the remaining individuals
for whom data were available was always below the 50th percentile and often near the 10th per-
centile. Severe developmental delay occurs in all individuals with SGS and 95% present with
epilepsy (n = 42/44). Almost all common types of epilepsy occur and seizures are characteristi-
cally extremely refractory to treatment with medication or ketogenic diet. Many patients have
hearing (n = 24/27) or vision impairment (n = 20/26) thought to be of cerebral origin. Spastic-
ity was noted in 17 out of 20 of cases.
Overlapping germline and somatic mutations in SETBP1
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Fig 1. Genetic and clinical characteristics of individuals with germline SETBP1 mutations and Schinzel-Giedion
syndrome. A. Schematic representation of the SETBP1 protein, indicating changes found in SGS and in hematologic
malignancies. The residues of the canonical degron are highlighted with arrows. Protein domains of SETBP1 are shown in
different colors with green corresponding to three AT hooks, purple to the SKI homologous region, blue to the SET binding
domain and orange to a repeat domain (modified from Piazza et al.). B. Sequence alignment of the region containing the
degron of SETBP1 (in bold) in human (Uniprot accession number Q9Y6X0), chimpanzee (H2QEG8), mouse (Q9Z180),
chicken (A0A1D5PT15), african clawed frog (F6TBV9) and zebrafish (B0R147). The consensus motif for βTrCP1 substrates
Overlapping germline and somatic mutations in SETBP1
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Structural brain abnormalities are variable in SGS. The most common anomaly is hypopla-
sia or aplasia of the corpus callosum (n = 31/38). Additional abnormalities often encountered
are cortical atrophy (n = 18/33), ventricle anomalies (n = 26/42), abnormal gyration and
delayed myelination and choroid plexus cysts (n = 13/31).
Additional congenital anomalies. Individuals with SGS nearly always present hydrone-
phrosis (n = 45/47), a feature that can be detected during routine prenatal medical exams. Two
patients in our cohort were noted to have hydronephrosis at 20 weeks of gestation. Other kid-
ney anomalies include abnormal ureters, renal cysts and stones. Almost all patients have geni-
tal anomalies (n = 41/45), which include hypospadias, underdeveloped genitalia and displaced
is shown on top, with φ representing a hydrophobic residue and X any amino acid. Residues in which pathogenic germline
mutations have been identified in classic SGS are highlighted in blue, while residues in which novel mutations leading to an
atypical form of SGS are shown in green. C. Distinctive facial features encountered in classic SGS (current case 9 at 1,5 years
of age). D. Typical question mark-shaped ear observed in current case 18. E. Characteristic hand posture with clenched
fingers from current case 16. F. Facial features of current case 27 with a mutation in SETBP1 residue S867 at 4 years of age.
Note the clenched fingers. G. Facial features of current case 28 with a mutation in SETBP1 residue E862 at 5 years of age. H.
Facial features of current case 29 with a mutation in SETBP1 residue T873 at the age of 23 months.
https://doi.org/10.1371/journal.pgen.1006683.g001
Table 1. Major clinical findings in 51 individuals with germline mutations in SETBP1. NA stands for “Not Assessed”.
Residue affected in SETBP1 E862 S867 D868 S869 G870 I871 T873 All degron-affecting
mutations (868–871)
Male(M):female(F) 1F 2 F 8F:7 M 2F 5F: 10M 6F:9M 1M 21F:26M
Craniofacial findings
Microcephaly 1/1 1/2 10/12 1/2 10/13 8/11 0/1 29/39 74.4%
SGS facial gestalt 0/1 2/2 15/15 2/2 15/15 15/15 0/1 47/47 100.0%
Congenital anomalies
Hydronephrosis 0/1 0/2 15/15 2/2 14/15 14/15 0/1 45/47 95.7%
Genital abnormalities 1/1 0/2 14/15 1/2 14/15 12/13 0/1 41/45 91.1%
Cardiac defects 0/1 1/2 10/15 1/2 4/13 5/13 0/1 20/43 46.5%
Tracheo/laryngomalacia 0/1 0/1 3/4 0/2 3/8 2/2 0/1 8/16 50.0%
Inguinal hernia 0/1 0/1 2/4 0/2 6/8 0/1 0/1 8/15 53.3%
Alacrima 0/1 2/2 6/10 0/2 7/9 6/6 0/1 19/27 70.4%
Neurodevelopmental anomalies
Developmental delay 1/1 2/2 14/14 2/2 13/13 10/10 1/1 39/39 100.0%
Seizures 0/1 2/2 15/15 2/2 13/14 12/13 0/1 42/44 95.5%
Spasticity and/or hypertonia 0/1 1/1 4/4 1/2 8/10 4/4 1/1 17/20 85.0%
Vision impairment 1/1 1/1 7/10 1/2 7/8 5/6 0/1 20/26 76.9%
Hearing impairment 0/1 0/1 9/9 0/1 7/8 8/9 0/1 24/27 88.9%
Progressive failure to thrive 0/1 0/1 10/11 1/2 13/13 8/9 0/1 32/35 91.4%
Brain MRI/CT
Ventriculomegaly 0/1 NA 6/12 2/2 11/14 7/14 0/1 26/42 61.9%
Underdeveloped corpus callosum 0/1 NA 9/11 0/2 12/13 10/12 0/1 31/38 81.6%
Cortical atrophy or dysplasia 0/1 NA 8/10 0/2 7/10 3/11 1/1 18/33 54.5%
Choroid plexus cysts 0/1 NA 2/9 0/2 8/10 3/10 0/1 13/31 41.9%
Radiological findings
Sclerotic base of skull or mastoid NA NA 9/10 0/1 5/5 5/7 NA 19/23 82.6%
Hypoplastic distal phalanges 0/1 NA 8/9 0/1 8/9 5/6 NA 21/25 84.0%
Broad ribs 0/1 NA 10/13 2/2 6/7 9/9 NA 27/31 87.1%
Hypoplastic/underossified pubic bones 0/1 NA 6/7 2/2 4/5 6/6 NA 18/20 90.0%
Tumors 0/1 0/2 5/11 0/2 1/11 1/9 0/1 7/33 21.2%
https://doi.org/10.1371/journal.pgen.1006683.t001
Overlapping germline and somatic mutations in SETBP1
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anus. Half of the patients (n = 20/43) have structural cardiac malformations, the majority of
which present with defects of the atrial septum. Other anomalies include patent foramen
ovale, patent ductus arteriosus and cardiac hypertrophy. Alterations in the internal organs
may be identified in some individuals with SGS, including hypoplasia of the pancreatic tail or
hepatosplenomegaly. Microscopic evaluation in one patient (current patient 6) showed dilated
glands and mucus depositions in intra-acinar pancreatic ducts at a post-mortem examination
at 4 days of age. The observed features were similar to the mucus obstruction seen in cystic
fibrosis. However, CFTR analysis in this patient proved negative. Nineteen patients (n = 19/27)
were noted to have alacrima. Inguinal hernia (n = 8/15) and talipe(s) equinovarus (n = 11/17)
were also frequently noted.
Swallowing and breathing difficulties. A major medical problem encountered in the
care of individuals with SGS is the difficulty in swallowing and breathing. This is caused by a
combination of factors such as structural abnormalities of the respiratory apparatus (e.g. choa-
nal stenosis, n = 10/34), tracheobronchomalacia (n = 8/16), lung hypoplasia, poor manage-
ment of oral and respiratory secretions (e.g. resulting from micrognathia, gingiva hypertrophy
or excessive mucus production) and a high susceptibility to airway infections. Although gin-
giva hypertrophy can result from the use of anti-epileptic medication, this feature was already
noted in a newborn with SGS at four days of age (patient 6). In this case, dilated laryngeal and
broncheal glands filled with mucus were observed in the microscope, consistent with a previ-
ous report of thickened alveolar mucosa and fibrous hyperplasia of the gingiva with mucoid
depositions [20], suggesting that this is a feature of SGS.
Cause of death. Most affected individuals do not survive past childhood, with pneumonia
as a major cause of death in SGS (n = 8/15). Other reported causes in early infancy include
congenital cardiac defects, tumors, lung hypoplasia, intractable seizures and sudden cardiac
arrest. Six individuals developed solid tumors, predominantly of neuroepithelial origin in the
lumbosacral region. Additionally, one individual in this cohort developed juvenile myelomo-
nocytic leukemia. Although the majority of individuals die during infancy, five out of twelve
patients with a protein substitution in residue G870 lived to the age of 5 or older (5 to 15 years
of age). The average age of death of deceased individuals with a substitution in D868, S869,
G870 and I871 is 18 months (n = 10), 32 months (n = 2), 48 months (n = 7) and 25 months
(n = 8), respectively (see S2 Fig). Due to the small size of the cohort, it is not possible to draw
conclusions on whether there are differences in survival depending on the mutated residue.
Individuals with mutations outside of the degron. Individuals with germline SETBP1
mutations occurring outside the degron (n = 4) are reported in this separate section. Both
patients with a mutation in residue S867 (one reported in [21] and current case 27 from our
cohort, see Fig 1F and S3A–S3D Fig) had a characteristic facial appearance, genital anomalies
and seizures but did not show hydronephrosis. Other features of these patients fit within the
spectrum of SGS and are summarized in Table 1 and S1 Table.
One individual with a mutation in residue E862 did not have a characteristic facial appear-
ance (Fig 1G and S3E–S3H Fig), seizures nor hydronephrosis. However, this patient had sev-
eral other overlapping features with SGS, including dysphagia requiring a gastrostomy tube,
vision loss due to retinal dystrophy, bilateral renal cysts and severe spasticity. She showed
microcephaly, prognathism, small feet with short toes and a normal height. At five years of
age, she had severe intellectual disability and could neither speak nor walk.
The individual with a mutation in residue T873 had the mildest phenotype, presenting with
developmental delay, autistic features, spastic diplegia and milder dysmorphic features (Fig 1H
and S3I–S3L Fig). This patient does not present any of the major congenital anomalies com-
monly found in SGS and, despite developmental delay, his initial developmental outcome
seemed higher compared to individuals with SETBP1 mutations within the degron. He
Overlapping germline and somatic mutations in SETBP1
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achieved several milestones: smiling at eight weeks, making vowel sounds at 14 months, sitting
unassisted at 22 months and, at 2 years of age, he was able to maintain crawling position, walk
with help and feed himself. Thereafter, he entered a regression phase with loss of the aforemen-
tioned milestones and started self-injurious behavior. An IQ test was not available but, at 4
years of age, his functional level was estimated to be that of an eight-month-old.
Functional characterization of SETBP1 variants
Mutations within the canonical degron of SETBP1 disrupt its interaction with βTrCP1,
increasing protein stability and SETBP1 levels [5,15] but the effect of SETBP1 mutations out-
side the canonical degron on protein stability is unknown. Clear differences in the severity of
the phenotype resulting from germline SETBP1 mutations within and outside the canonical
degron suggest a difference in the effect of the mutations depending on their localization.
Therefore, we performed the functional characterization of the most frequent SETBP1 muta-
tions observed within the canonical degron and causative for classic SGS (D868N, S869N,
G870S and I871T) as well as one mutation outside the canonical degron leading to atypical
SGS (E862K).
Effects of SETBP1 variants on protein levels and protein stability. To investigate the
effect of SETBP1 variants on protein stability, we quantified expression levels of YFP-fusion
proteins in live HEK293 cells based on fluorescence intensity (S4 Fig). All three pathogenic
SETBP1 variants E862K, D868N and I871T showed increased protein levels compared to WT
SETBP1 (Fig 2A; p<0.001, ANOVA). Interestingly, SETBP1 variants occurring within the
canonical degron (D868N, I871T) showed higher protein levels compared to the variant adja-
cent to the degron sequence (E862K; p<0.001 versus other mutants, ANOVA).
To verify that the increased protein levels seen in cells expressing pathogenic SETBP1 vari-
ants are due to resistance to degradation by the proteasome, we treated transfected HEK293
cells with MG132, a proteasome inhibitor (Fig 2B). WT SETBP1 protein levels were sensitive
to inhibition of the proteasome, as evidenced by a significant increase in fluorescence intensity
after MG132 treatment for 3 hours (132% vs 108% for treated versus untreated cells compared
to baseline, p<0.05, Student’s T-test). The difference in expression levels after 3 hours of
MG132 treatment was not significant for SETBP1 variants E862K, D868N and I871T (E862K:
126% vs 113%; D868N: 118% vs 115%; I871T: 121% vs 121% for treated versus untreated cells
compared to baseline). Prolonged treatment with MG132 resulted in a larger fold increase in
fluorescence observed for treated versus untreated cells in cells transfected with WT versus
mutant SETBP1 (1.58 for WT, 1.32 for E862K, 1.14 for D868N and 1.21 for I871T; p<0.01,
ANOVA). Indeed, prolonged MG132 treatment results in a significant increase in expression
levels of wildtype SETBP1 and the E862K mutant (SETBP1: 261% vs 164%; E862K: 230% vs
173% for treated versus untreated cells compared to baseline, p<0.001, Student’s T test). Pro-
longed MG132 treatment did not significantly affect the expression levels of the D868N and
I871T SETBP1 variants (211% vs 185% and 225% vs 186% for treated versus untreated cells
compared to baseline, respectively). Cycloheximide chase of wild-type and mutant SETBP1
suggests decreased degradation of mutant SETBP1 as compared to the wild-type protein (S5
Fig), further supporting that mutations in the SETBP1 degron confer increased stability to the
protein. This suggests that pathogenic SETBP1 variant proteins have decreased sensitivity or
resistance to proteasome inhibition with varying magnitude of effects.
Different magnitude of effect of SETBP1 variants within the canonical degron. To
explore the effect of disease-causing SETBP1 variants on the interaction of SETBP1 with
βTrCP1, we performed in silico modeling of all known germline mutations that occur within
the canonical degron (D868-I871) identified in patients with classic SGS. Although the protein
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structure of SETBP1 is not known, the sequence of the βTrCP1 binding site in the SETBP1
degron is similar to the sequence of a degron in β-catenin (S2 Table) [18]. We therefore used a
protein model of the degron of β-catenin in complex with βTrCP1 as a template to analyze
the effect of pathogenic germline SETBP1 variants on molecule stability and on the degron/
βTrCP1 interaction energy (molecule ΔΔG and βTrCP1 interaction ΔΔG, respectively; Fig 2C
and S3 Table). Modeling of all pathogenic germline substitutions observed in the degron
shows that the interaction with βTrCP1 was most affected for substitutions of the aspartate res-
idue from the motif (p<0.01 versus other residues, ANOVA), which is in line with previous
findings [18]. This would entail that among the variants observed in SGS, mutations in residue
D868 would have the largest effect on degron/βTrCP1 interaction, followed by mutations in
G870.
To verify the differences on protein stability observed at the computational level, we used
immunoblotting to examine the protein levels of SETBP1 variants in transfected HEK293
cells. Pathogenic SETBP1 variants led to substantially higher protein levels than WT SETBP1
Fig 2. Functional analysis of SETBP1 mutations identified in SGS. A. Fluorescence measurements in live HEK293 cells
expressing YFP-tagged SETBP1 variants. (*** p<0.001 versus wild-type and all mutants, ANOVA). All SETBP1 mutations studied
displayed a statistically significant difference compared to wild-type and to all other mutations. This graph is representative of 3
independent experiments performed, with 6 technical replicates per experiment. Bars represent the standard error. B. Relative
expression of SETBP1 protein variants in live HEK293 cells treated with MG132 proteasome inhibitor or vehicle only. Bars represent
the standard error. (*** p<0.001, * p<0.05, NS: not significant, Student’s T test and Mann-Whitney U test). C. ΔΔG values for
degron-βTrCP1 interaction for all germline mutations reported in SETBP1 per residue (** p<0.01 D868 versus other residues;
ANOVA). D. Immunoblot of whole cell lysates of HEK293 cells expressing FLAG-tagged SETBP1 variants probed with anti-FLAG
antibody. E. Immunoblot of whole-cell lysates of fibroblasts probed with anti-SETBP1 antibody. Fibroblasts were derived from two
cases of SGS, one carrying the I871T variant and the other carrying the D868N variant, as well as from two unrelated controls. In D
and E, blots were stripped and re-probed with anti-β-actin antibody.
https://doi.org/10.1371/journal.pgen.1006683.g002
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(Fig 2D and S6 Fig). Variants D868N and G870S resulted in dramatically increased protein
levels, whereas E862K, S869N and I871T showed a more modest increase in protein levels (Fig
2D). To further explore these findings, we performed immunoblotting to examine endogenous
SETBP1 protein levels in fibroblasts derived from individuals with SGS. Fibroblasts from an
individual carrying the D868N variant showed increased SETBP1 protein levels compared to
two unrelated age-matched controls, whereas fibroblasts from a patient carrying the I871T
mutation did not show any differences in endogenous SETBP1 levels compared to the controls
(Fig 2E). Analysis of mRNA levels showed decreased SETBP1 mRNA levels in cells of individu-
als with SGS as compared to controls, suggesting that the increase observed in endogenous
SETBP1 protein does not result from increased SETBP1 transcription (S7 Fig). Together, these
results suggest that SETBP1 degron mutations have variable effects on protein stability, with
the D868N variant having a stronger effect than I871T.
Overlapping SETBP1 mutations in SGS and in myeloid malignancies. Overlapping
mutations in SETBP1 have been identified as germline de novo events in SGS and as somatic
mutations in myeloid malignancies (Fig 1A). Considering that canonical degron mutations
vary in the magnitude of their effect, we compared germline and somatic SETBP1 mutations to
detect differences between the mutations in both conditions. In total, 48 germline de novo
mutations within the SETBP1 degron have been reported in individuals with SGS, both from
our cohort and from published literature (see S4 Table) [4,21–29]. Similarly, we have retrieved
from literature 245 individual somatic mutations in the SETBP1 degron, associated with differ-
ent myeloproliferative disorders (see S4 Table) [5–7,30–48]. While the mutations overlap in
both conditions, the distribution of the mutations within the canonical degron sequence is not
the same; a significantly higher number of mutations affect residue I871 in SGS cases com-
pared to myeloid malignancy cases (29% and 12%, respectively, p<0.01, Fisher’s test with Bon-
ferroni correction; see Fig 3A).
All SETBP1 degron mutations identified in leukemia were compared to mutations
observed in SGS on their effect on the SETBP1-βTrCP1 interaction using in silico modeling
(Fig 3B). Taking into account the frequency of each mutation, we then compared the differ-
ence in degron-βTrCP1 interaction energy for SETBP1 mutations observed in SGS versus
those observed in myeloid malignancies (Fig 3C). Generally, mutations observed in myeloid
malignancies showed higher ΔΔG values than mutations observed in SGS (p <0.05, Mann-
Whitney’s U test). However, the difference in ΔΔG between germline and somatic SETBP1
mutations after exclusion of mutations in codon I871 is no longer statistically significant.
This suggests that the difference between ΔΔG values between germline and somatic SETBP1
mutations may be secondary mainly to the prevalence of mutations at codon I871 in each
condition.
Similarities in downstream consequences of germline and somatic SETBP1 muta-
tions. The SETBP1-SET interaction regulates SET protein levels and can induce cleavage of
SET [16]. Higher levels of SET protein have been reported with overexpression of wildtype
SETBP1 in HEK cells and of SETBP1 G870S in TF1 cells [5,16]. To establish whether patho-
genic germline SETBP1 degron mutations D868N, S869N and I871T also lead to increased
SET protein levels in SGS, we performed immunoblotting on protein lysates of lymphoblastoid
cell lines (LCLs) derived from three unrelated patients with SGS. Compared to age-matched
controls, we observed that cell lines derived from individuals with germline mutations in the
SETBP1 degron show higher SET protein levels, with an increase in full length versus cleaved
SET protein (Fig 4A and 4B).
Somatic mutations in SETBP1 drive the development of myeloid malignancies by increas-
ing proliferation in leukemic cells [15]. We examined LCLs derived from individuals with
germline SETBP1 mutations seen in SGS to determine whether they presented increased
Overlapping germline and somatic mutations in SETBP1
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Fig 3. On average, SETBP1 mutations seen in cancer are more severe than those observed in SGS. A.
Distribution of mutations within the SETBP1 degron in SGS and in hematological malignancies. (** p<0.01,
Fisher’s test and Bonferroni correction for multiple testing). B. ΔΔG values for protein stability (x-axis) and
degron-βTrCP1 interaction (y-axis) for all mutations reported in SETBP1. The size of each circle is
proportional to the frequency of the mutation in each condition. C. Difference in free energy of binding in the
interaction between βTrCP1 and the degron of variants arising from germline or somatic SETBP1 mutations
compared to that of the interaction between βTrCP1 and the wild-type degron (* p <0.05, Mann-Whitney’s U
test). The median is highlighted by an arrow head.
https://doi.org/10.1371/journal.pgen.1006683.g003
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proliferation. In a time course experiment, we observed that LCLs derived from individuals
with SGS proliferate faster and have shorter doubling times than cells derived from age-
matched controls in a genotype-dependent manner (p<0.001 versus controls by ANOVA, see
Fig 4C and 4D). LCLs from unrelated individuals carrying D868N mutations had the shortest
doubling times, followed by LCLs from unrelated patients carrying I871T mutations and
by cells derived from age-matched controls (23.2, 27 and 33.8 hours respectively, p<0.05,
ANOVA). LCLs from an individual with a S869N mutation consistently showed lower prolif-
eration and longer doubling time (41.7 hours; Fig 4D). RNA sequencing of LCLs of individuals
with germline SETBP1 mutations revealed differential expression of 1811 genes between con-
trols and individuals with SGS (S8 Fig), of which 632 were upregulated and 1179 were downre-
gulated [49]. Gene set enrichment analysis of differentially expressed genes between controls
and individuals with germline SETBP1 mutations shows an enrichment for genes involved in
mRNA transcription and translation, mitochondrial respiration and cell cycle (S5 Table) [50].
Increased tumorigenesis in individuals with mutations in residue D868. To determine
whether a correlation exists between the magnitude of effect of a germline SETBP1 mutation
and tumorigenesis in individuals with SGS, we examined the clinical data of our cohort and
previously published mutation-positive cases. In total, 7 malignancies have been reported in
mutation-positive individuals, of which 5 occurred in patients with mutations in residue D868
(four tumors of primitive neuroectodermal origin and one myeloid leukemia). The remaining
Fig 4. Increased SET protein and proliferation in cell lines of patients with SGS. A. Immunoblot of whole cell lysates of
lymphoblastoid cell lines (LCLs) derived from three SGS patients and two age-matched controls. The blot was probed with anti-
SET, before stripping and re-probing with β-actin to confirm equal loading. * denotes full-length SET protein (37kDa), arrowhead
denotes cleaved SET protein (22kDa). B. SET protein levels as determined by densitometric analysis of Western blot data and
normalized to actin (n = 2 independent experiments). Bars represent the standard error. C. Proliferation assay of LCLs derived
from SGS individuals and age-matched controls over 3 days (*** p< 0.001 versus controls, ANOVA). Bars represent the
standard error. D. Mean doubling time for LCLs derived from individuals with germline SETBP1 mutations compared to controls
over 3 days (* p<0.05 versus controls, ANOVA). The mean of two experiments is shown, bars represent the standard error.
https://doi.org/10.1371/journal.pgen.1006683.g004
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tumors included one ependymal tumor with myxopapillary and ependymoblastic differentia-
tion in an individual with mutation G870D and one primitive neuroectodermal tumor in an
individual with mutation I871T.
To compare the intensity of effect of mutations in the group of individuals who developed
cancer versus those who did not, we calculated the median SETBP1-βTrCP1 interaction ΔΔG
value for each group based on results from in silico protein modeling (Figs 3B and 5). The
Fig 5. Functional effects of germline SETBP1 mutations and risk of malignancy. Degron-βTrCP1
interaction ΔΔG for SETBP1 mutations in individuals with SGS who did not develop a malignancy versus
those who did (*p<0.05, Mann-Whitney’s U test). The median for each group is marked by an arrowhead. The
criteria to be considered negative for the development of a malignancy was either reaching the age of 60
months or dying without developing a malignant tumor or leukemia.
https://doi.org/10.1371/journal.pgen.1006683.g005
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group of individuals who developed cancer carry SETBP1 mutations which are more disrup-
tive to the interaction of SETBP1 with βTrCP1 than the group of patients who did not develop
cancer (Fig 5; βTrCP1 interaction ΔΔG = 3.57 vs 0.65, p = 0.029, Mann-Whitney U test).
Finally, we analyzed the prevalence of malignancy per genotype in 33 mutation-positive indi-
viduals with SGS for whom we had data. While the incidence of tumorigenesis is 21.2% in this
pooled group, individuals with mutation D868 have a statistically significantly higher risk of
developing tumors than individuals with other germline mutations in SETBP1 (OR = 9.16,
95% CI = 1.4–59.6, p = 0.02). Remarkably, mutations in residue D868 represent the most prev-
alent mutation observed somatically in cancer.
Discussion
The aims of our study were: to present the phenotype of the largest cohort of individuals with
SGS and germline SETBP1 mutations, establish genotype-phenotype correlations for germline
SETBP1 mutations and, by using these and previous findings from cancer research, provide
insight into the molecular mechanism of SGS.
We present the clinical features of 47 individuals with “classic” SGS caused by germline
mutations in SETBP1 affecting the canonical degron (D868-I871). All mutations were found
de novo in the affected proband, although two individuals in our cohort were siblings carrying
the same disease-causing mutation in residue I871. This recurrence suggests parental mosai-
cism as the origin of the mutation but we were unable to detect the mutation in DNA from
parental blood samples by deep sequencing. Interestingly, the first published report of SGS in
1978 described two siblings with the phenotype, which initially led to believe that this disorder
was inherited autosomal recessively [1].
SGS is a rare but clinically recognizable developmental disorder consisting of typical facial
features, neurological alterations, various congenital anomalies and increased risk of malig-
nancy. Neurological problems often encountered include severe intellectual disability, intrac-
table epilepsy and cerebral blindness and deafness. Individuals with SGS frequently present
with congenital anomalies in multiple organ systems including heart defects, kidney and/or
genital malformations and bone abnormalities. Most affected individuals do not survive past
childhood due to the severity of this disorder.
Four additional individuals presented a developmental phenotype with clinical characteris-
tics overlapping classic SGS caused by atypical SETBP1 mutations in close proximity to the
canonical degron. SGS is often recognized and diagnosed based on the reminiscent clinical fea-
tures and, interestingly, the amount of clinical overlap with SGS seems to be related to the
position of the mutation in relation to the canonical degron. Both individuals carrying a muta-
tion affecting SETBP1 residue S867 had the characteristic facial features of SGS, genital anom-
alies and seizures but no hydronephrosis. The absence of hydronephrosis in these cases is
remarkable, since it is considered one of the hallmark features of SGS [51]. However, hydrone-
phrosis was also absent in two individuals with mutations within the degron, suggesting that it
should not be recognized as an obligatory feature for the diagnosis of SGS. Although both indi-
viduals with an atypical SETBP1 mutation in residues E862 and T873 share some features with
SGS, they would not have been classified as typical SGS. In both these individuals, the muta-
tions were detected by whole exome sequencing and lead to the diagnosis of atypical SGS a
posteriori. Therefore, as Carvalho et al. recently suggested [21], previously proposed clinical
diagnostic criteria for SGS may not be applicable for these cases. Due to the limited number of
atypical cases, we cannot draw any conclusions on the survival and progress of the disease in
these cases.
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Somatic SETBP1 mutations observed in myeloid malignancies have been shown to have a
gain-of-function effect on the SETBP1 protein, leading to decreased binding of the βTrCP1
and increased protein levels [5]. This gain-of-function mechanism seems to also pertain to
germline SETBP1 mutations, as we observe that cells of individuals with germline SETBP1
mutations have increased levels of SETBP1 protein. Furthermore, recent reports of germline
chromosomal deletions and truncating mutations in SETBP1 show that loss-of-function muta-
tions in this gene cause a completely different phenotype from SGS [52]. Clinically, individuals
with these genetic lesions present a phenotype characterized by a complete lack of expressive
speech with intact receptive language abilities, decreased fine motor skills, subtle dysmorph-
isms and hyperactivity and autistic traits [53].
The distribution of germline SETBP1 mutations within the canonical degron differs from
that of somatic events; mutations affecting residue I871 are significantly more frequent in the
germline than somatically. Furthermore, germline SETBP1 mutations are on average less dis-
ruptive to the βTrCP1-SETBP1 interaction than somatic mutations. Notably, the isoleucine at
position 871 is a variable residue within the SETBP1 degron, which is defined as “DpSGφXpT”
where φ (in this case, isoleucine) represents a hydrophobic amino acid and X stands for any
residue [18]. Previous studies of the structure of the conserved destruction motif in β-catenin
show that the isoleucine residue in the degron has a small role in the interaction with βTrCP1,
while the first three residues of the degron and the asparagine in particular are essential for
protein-protein binding [18]. Thus, the molecular differences observed between germline and
somatic SETBP1 mutations are likely caused by variation in the prevalence of mutations in res-
idue I871 in each condition. As a consequence of the weak role of residue I871 in the interac-
tion of SETBP1 with βTrCP1, mutations in this residue, although disruptive when present in
the germline, are functionally milder.
The difference in molecular consequences between somatic and germline SETBP1 muta-
tions is in line with findings from previous studies examining somatic and germline mutations
in PTPN11, involved in juvenile myelomonocytic leukemia and in Noonan syndrome, respec-
tively [54,55]. In contrast with SETBP1 mutations, germline PTPN11 mutations causative for
Noonan syndrome rarely overlap with somatic mutations observed in leukemia. This mutual
exclusivity between germline and somatic PTPN11 mutations has been proposed to result
from the existence of distinct thresholds for gain-of-function mutations in developmental phe-
notypes and tumorigenesis [55]. Despite their overlap, our analysis of germline and somatic
SETBP1 mutations supports this model. Malignant cell behavior in cancer can only be driven
by somatic mutations with intense activation, while germline mutations with mild activation
are sufficient to disrupt normal development. Consequently, gain-of-function mutations usu-
ally found somatically may lead to prenatal lethality or severe developmental alterations when
present in the germline, as a result of intense activation [56]. Likewise, mild hypermorphic
mutations associated with developmental disorders may be less likely to drive malignancy and
are encountered less frequently as somatic events in cancer. In line with this, functional analy-
sis of D868N, the SETBP1 mutation most commonly found in cancer, shows that it leads to the
highest increase in SETBP1 protein levels and cell proliferation, suggesting it has the strongest
effect at the biochemical and cellular level. Remarkably, individuals with SGS caused by muta-
tions in residue D868 have higher incidence of tumorigenesis with odds ratio above 9 when
compared to individuals with SGS caused by other mutations. Our findings suggest that indi-
viduals with strongly activating germline mutations in SETBP1 are at increased risk of malig-
nancy. Due to the extremely low prevalence of SGS and the fact that malignancy is still a
relatively infrequent complication of SGS, our study is limited by the small number of individ-
uals with SGS who developed a malignancy. The correlation between strongly activating germ-
line SETBP1 mutations and risk of malignancy should be reproduced in a larger cohort, in
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order to provide accurate prognosis and personalized follow up for individuals with germline
SETBP1 mutations.
Despite the increased risk for tumorigenesis, most individuals with SGS do not develop
cancer. This observation that can be extended to individuals with developmental disorders
resulting from germline mutations in genes involved in cancer when mutated somatically such
as ASXL1, EZH2 or ARID1A [57–59]. As mentioned previously, this observation may be in
part due to the effect of germline mutations not reaching the threshold of functional activation
required to drive cancer. Furthermore, early lethality could also explain why most individuals
with developmental disorders caused by germline mutations in genes involved in cancer do
not develop malignancies. For instance, somatic SETBP1 mutations have been associated
mainly with chronic myeloid leukemia, a disease occurring generally in individuals above
the age of 60 [5,31]. Individuals with SGS have a short life span, which may not allow for the
accumulation of additional somatic mutations required for tumorigenesis. Additionally, the
cellular context is also important for the expression of a mutation: certain cancer-driving
mutations can only do so in the context of “aged” hematopoietic stem cells [60–62]. This com-
bination of factors may explain why myeloid malignancy is a rare malignancy in SGS, while
embryonic cancers are observed more frequently. Finally, the presence of mutations in all
cells of the organism instead of a subset may eliminate cellular advantage in a single cell which
would allow for clonal expansion and, eventually, malignancy.
Cell lines derived from individuals with SGS recapitulate some of the features identified in
myeloid cells with SETBP1 mutations, including increased SETBP1 and SET protein levels and
enhanced cell proliferation [5,7]. Although we observed a SETBP1 mutation-specific effect on
cell proliferation, we did not detect visible differences in SET protein levels between individu-
als with different SETBP1 mutations. It is possible that different SETBP1 mutations have a sub-
tle but distinct effect on SET protein levels that are not detectable by Western blot. However,
we cannot rule out the absence of a mutation-specific effect of SETBP1 mutations on SET pro-
tein levels with additional mutation-specific downstream alterations resulting from pathways
that do not involve SET protein. In light of our findings, cell lines derived from patients with
developmental disorders caused by germline mutations in genes implicated in tumorigenesis
may be a valuable model for the study of downstream consequences of cancer mutations at
the molecular level. Furthermore, the similarities observed in the molecular consequences of
germline and somatic SETBP1 mutations support the rationale behind recent studies which
have elegantly repurposed drugs used in cancer therapy for the treatment of developmental
disorders in mouse models [63]. An increase in SETBP1 protein as a result of mutations or
overexpression leads to an increase in SET protein which results in the inactivation of PP2A.
Although currently there are no known SETBP1 antagonists, several compounds have been
described to antagonize SET protein or to lead to PP2A activation [64]. For example, OP449 is
a synthetic peptide that binds to SET protein, activates PP2A and selectively inhibits cell
growth in leukemia cell lines and primary patient cells [65]. Other compounds that directly
activate PP2A, such as FTY720, have also been described [66]. While promising, it is yet
unclear whether compounds targeting SET or PP2A may prove useful in the treatment of indi-
viduals with germline SETBP1 mutations. For one, the window of time between diagnosis and
potential therapeutic interventions for early developmental phenotypes may be minimal. How-
ever, although this is still a speculative point, future therapeutic interventions may be useful to
prevent progression of certain features of SGS, such as neurodegeneration [28]. Finally, it is
still possible that individuals with SGS present alterations in other proteins downstream of
SETBP1.
In summary, we describe the largest cohort of SETBP1 mutation-positive SGS patients to
date. Our results support that typical SGS is caused by gain-of-function mutations of SETBP1
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affecting a degron involved in SETBP1 protein stability, while novel mutations outside the
canonical degron cause an atypical form of SGS characterized by a milder phenotype. We
observe variability in the magnitude of effect of germline mutations within the canonical
degron of SETBP1 with consequences at the biochemical level and influencing the cellular and
clinical phenotype. Furthermore, our results highlight that, despite the identification of over-
lapping SETBP1 mutations in SGS and myeloid malignancies, the mutation spectrum is
significantly different in both conditions with functionally weaker mutations appearing pre-
dominantly as germline mutations in SGS. The parallelisms between the functional conse-
quences of germline and somatic SETBP1 mutations is relevant for the better understanding
of SGS but could also deliver insight into the role of SETBP1 as a cancer driver. Finally, our
findings highlight that the convergence of the fields of cancer and developmental disorders
uncovers common molecular mechanisms of disease for overlapping germline and somatic
pathogenic mutations and may support the development of drugs with a dual therapeutic role
in developmental disorders and cancer.
Materials and methods
Ethics statements
This study was approved by the institutional review board "Commissie Mensgebonden Onder-
zoek Regio Arnhem-Nijmegen" NL36191.091.11. Parents of all patients provided their written
consent.
DNA studies
Genomic DNA was extracted from saliva or blood using the QIAamp DNA Mini kit (QIA-
GEN). The hotspot region of SETBP1 was amplified by PCR and Sanger sequenced. Primer
sequences are listed in S6 Table.
Phenotyping of individuals with SGS
Clinical features of participants were initially evaluated by clinicians from various countries.
Photographs and medical information of all individuals were further assessed by a single
clinical geneticist (BWvB). Separate informed consent was obtained for publication of
photographs.
DNA constructs
The full-length SETBP1 construct fused to a C-terminal Myc-FLAG tag was purchased from
Origene (RC229443). SETBP1 variant constructs were generated using the Quikchange II Site-
Directed Mutagenesis kit (Agilent). Primer sequences are listed in S5 Table. SETBP1 cDNAs
were subcloned using EcoRI/XhoI restriction sites into a modified pEGFP-C2 vector (Clon-
tech) where the N-terminal EGFP tag was replaced with a YFP tag. All constructs were verified
by Sanger sequencing.
Cell culture and transfection
Fibroblast cell lines were established from skin biopsies of SGS cases and controls. HEK293
cells and fibroblasts were cultured in DMEM supplemented with 10% fetal bovine serum (all
from Invitrogen). LCLs were established by Epstein-Barr virus transformation of peripheral
lymphocytes from blood samples of SGS patients and controls. LCLs were cultured in RPMI
medium (Lonza) with 10% fetal bovine serum and 5% HEPES. Transfections were performed
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using the GeneJuice transfection reagent following the manufacturer’s instructions (Merck
Millipore).
Western blotting
Whole-cell lysates were prepared as described previously [67]. Total protein was quantified
using the Pierce BCA protein assay kit (ThermoFisher Scientific). Proteins were resolved on
4–15% Tris-Glycine gels and transferred to PDVF membranes (Bio-Rad). After blotting, mem-
branes were incubated overnight at 4˚C with the appropriate primary antibodies: rabbit anti-
SETBP1 (Santa Cruz, sc-85148, 1:100), rabbit anti-SET (Abcam, ab1183, 1:4000), mouse anti-
β-actin (Sigma, AC-15, 1:10000) and mouse anti-FLAG (Sigma, F1804; 1:1000). Membranes
were then incubated with HRP-conjugated donkey anti-rabbit (Abcam) or goat anti-mouse
(Bio-Rad) secondary antibodies. Proteins were visualized using the Novex ECL Chemilumi-
nescent Substrate Reagent kit (Invitrogen) and the ChemiDoc XRS+ System (Bio-Rad).
Protein stability assays
Cells were transfected in clear-bottomed black 96-well plates in hexaplicate with YFP-SETBP1
expression plasmids together with a modified pmCherry-C1 plasmid to normalize for transfec-
tion efficiency. Fourteen hours post-transfection, YFP and mCherry fluorescence intensities
were measured for 24h in live cells in a TECAN M200PRO microplate reader at 37˚C and 5%
CO2. In the case of stability assays with proteasome inhibitor, MG132 (Sigma) was added to
the culture medium (10uM final concentration) 48 hours post-transfection and fluorescence
intensities were measured at 0, 3 and 12 hours.
Fluorescence microscopy
Cells were grown on poly-L-lysine (Sigma) coated coverslips and were fixed 48 hours post-
transfection with 4% paraformaldehyde (Electron Microscopy Sciences) for 10 minutes at
room temperature. YFP was visualized by direct fluorescence. Nuclei were visualized with
DAPI (Vectorlabs). Fluorescence images were obtained using an Axio Imager Z1 fluorescence
microscope (Zeiss).
Proliferation assays
Lymphoblastoid cell lines were synchronized by overnight serum starvation, after which they
were seeded in 24-well plates at a concentration of 160,000 cells/mL (three replicates per cell
line). A measurement was performed every 24 hours, in which the cells were mixed with Try-
pan blue and counted.
Modeling of protein in Yasara and FoldX
The SETBP1 degron variants observed in SGS and in leukemia were manually curated from
previously published reports) [4–7,23–27,30–48]. Mutations were modeled using the YASARA
structural simulation software (http://www.yasara.org/). The protein model for βTrCP1 and
degron sequence from β-catenin was obtained from the RCSB protein bank (1p22) [18]. The
FoldX plugin for YASARA was used to calculate ΔΔG values [68].
RNA-sequencing
LCLs from individuals with SGS were derived from blood samples of individuals with germline
SETBP1 mutations D868N or I871T (n = 2 for each). LCLs from controls (n = 8) were derived
from blood samples of individuals with different forms of intellectual disability [69]. RNA was
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purified from cell cultures using RNeasy mini kit from QIAGEN. RNAseq libraries were pre-
pared using the TruSeq Stranded mRNA kit (Illumina) and sequenced on a Nextseq platform
using 2x75bp paired end sequencing. RNA-seq samples were mapped using Kallisto (version
0.42.4) to the human genome (hg19.75). At least 70% of the reads for each sample were
mapped to the human genome entailing at least 39.6 million reads in the sample with the low-
est sequencing depth. Differential gene expression was performed using DESeq2 [49]. Gene set
enrichment analysis was performed using the GSEA software [50].
Statistics
Statistical analysis was performed using R Statistical Software (http://www.r-project.org/ ver-
sion 3.1.2, R Foundation for Statistical Computing, Vienna, Austria). Student’s T test was used
for comparison of two groups with normal distribution, otherwise Mann-Whitney’s U test was
used. For comparison of multiple groups against each other, we used ANOVA and Tukey’s
test. To determine whether the distribution of mutations within the degron was the same in
germline and somatic mutations, we used Fisher’s test and performed Bonferroni multiple test
correction.
Supporting information
S1 Table. Table with all clinical information from 51 individuals with gain-of-function de
novo mutations within or in close proximity to the SETBP1 degron. Of these, 26 are novel
cases of classic SGS caused by mutations affecting SETBP1 residues D868-I871 and 3 are novel
individuals presenting an atypical form of SGS secondary to mutations affecting SETBP1 resi-
dues E862, S867 and T873.
(XLSX)
S2 Table. Protein sequence alignment of degrons targeted by βTrCP. Based on Low TY
et al. A systems-wide screen identifies substrates of the SCF bTRCP ubiquitin ligase. Sci Signal
2014; 7: 1–12
(PDF)
S3 Table. ΔΔG values for protein stability and degron-βTrCP1 interaction for SETBP1 var-
iants reported in SGS cases and in myeloproliferative disorders.
(PDF)
S4 Table. Table with germline and somatic SETBP1 mutations reported in literature.
Germline SETBP1 mutations were retrieved from previous reports from mutation-positive
individuals with SGS. Two siblings with the same germline SETBP1 mutation were identified
in our cohort, suggesting parental mosaicism for the pathogenic mutation. These two muta-
tions were counted as a single event. Somatic SETBP1 mutations were retrieved from the
Catalogue of Somatic Mutations in Cancer (COSMIC) database and the cited references were
manually curated to avoid double counts for a single mutation (e.g. sample from same patient
at diagnosis versus relapse).
(XLSX)
S5 Table. Gene set enrichment analysis for genes differentially expressed in LCLs from
individuals with germline SETBP1 mutations D868N or I871T and LCLs from controls.
Gene set enrichment analysis was performed as described in Subramanian et al. PNAS 2005
using curated gene sets from the reactome pathway database. An enrichment is observed for
genes involved in mRNA transcription and translation, mitochondrial respiration and in the
cell cycle. While no enrichment was observed for specific pathways, a closer examination of
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the genes involved in cell cycle that we detected to be enriched in the samples of individuals
with germline SETBP1 mutations revealed that the genes identified were associated with mito-
sis, sister chromatid cohesion, DNA replication and nucleosome assembly.
(PDF)
S6 Table. Sequences of primers used in this study.
(PDF)
S1 Fig. Facial features in typical Schinzel-Giedion syndrome. Panels A to I show the facial
features of patients with germline SETBP1 mutations within the canonical degron leading to
typical SGS (A: current case 1; B: current case 2; C: current case 3; D: current case 12; E: cur-
rent case 16; F: current case 18; G current case 20; H current case 23). Progression of facial fea-
tures with age in current case 9 with germline SETBP1 mutation G870S at 1 week of age (I), at
1½ years of age (J), at 6 years of age (K) and at 7 years of age (L).
(TIF)
S2 Fig. LogRank survival analysis performed for 44 individuals with SGS for which data
was available from our own cohort and previous reports. Dots represent censored data, for
age at which the individual was last known to be alive. The group of patients with mutations in
residue G870 had a statistically significantly longer survival than individuals with mutations in
residue D868 (median of 60 months versus 24 months respectively, p<0.01).
(TIF)
S3 Fig. Phenotype of individuals with germline SETBP1 mutations outside the canonical
degron leading to atypical Schinzel-Giedion. Individual with germline SETBP1 mutation
S867R (current case 27) at 1 week of age (A), at nine months (B), at two years of age (C) and at
four years of age (D). Patient with germline SETBP1 mutation E862K (current case 28) at 5
years of age (E and F). Right hand and foot (G and H), note the small feet with short toes. Indi-
vidual with germline SETBP1 mutation T873I (current case 29) at one month of age (I), at
eleven months (J), at three years of age (K) and at four years of age (L).
(TIF)
S4 Fig. Fluorescence imaging of HEK293 cells expressing YFP-tagged SETBP1 variants
(green). Nuclei were stained with DAPI (blue). Wild-type (WT) SETBP1 and disease-causing
SETBP1 variants were expressed in HEK293 cells as YFP fusion proteins. Direct fluorescence
imaging of SETBP1 variants showed that the WT protein localizes to the nucleus, with a
speckle-like pattern typical of chromatin-interacting proteins. Pathogenic SETBP1 protein var-
iants occurring within (D868N, I871) or in close proximity (E862K) to the canonical degron
sequence had no effect on protein localization.
(TIF)
S5 Fig. Relative expression of SETBP1 protein variants in live HEK293 cells treated
with 50ug/uL cycloheximide or vehicle only as controls. Bars represent the standard error.
( p<0.05,  p<0.01,  p<0.001 versus cells at same time point treated with vehicle; Stu-
dent’s T test and Mann-Whitney U test for measurements with non-normal distribution). The
fold decrease in relative expression at 24 hours is significantly higher for wild-type SETBP1
compared to all variants.
(TIF)
S6 Fig. Densitometry for Western blot of overexpressed wild type and mutant SETBP1-
FLAG in HEK293 cells using actin for normalization.
(TIF)
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S7 Fig. Levels of SETBP1 mRNA in fibroblasts and Lymphoblastoid Cell Lines (LCLs) from
individuals with SGS as compared to controls. SETBP1 mRNA levels were normalized to
ACTB and GAPDH. The results shown represent the mRNA levels in fibroblasts cells lines
from 2 controls, fibroblast cell lines from 2 individuals with SGS, LCLs from 2 controls and
LCLs from 3 individuals with SGS. The bars represent the standard error. NS: not significant.
 p<0.01, Student’s T test. The decrease in SETBP1 mRNA levels observed in individuals with
SGS compared to controls could be the result of a feedback mechanism in which increased
SETBP1 protein levels may lead to a reduction in SETBP1 transcription thereby decreasing
SETBP1 protein levels. A similar observation was reported for myeloid progenitor cells
immortalized by mutant SETBP1 compared to cells immortalized by wild-type SETBP1 in
Makishima H. et al. Nat Genetics 2013. We speculate that this mechanism would be able to
lower SETBP1 protein to normal levels for SETBP1 harboring weaker mutations, such as
I871T, but not for stronger mutations, such as D868N.
(TIF)
S8 Fig. Heatmap of RNAseq transcriptome analysis showing differential gene expression
between LCLs from controls (n = 8) and LCLs from individuals with germline SETBP1
mutations D868N or I871T (n = 2 for each). Only the top 250 most significant genes are
shown in this figure. Yellow indicates high expression while red indicates low expression. Dif-
ferential gene expression was performed using DESEq2, which showed differential expression
of 1811 genes (adjusted p-value <0.01), of which 632 are upregulated and 1179 are downregu-
lated.
(TIF)
Acknowledgments
We would like to thank the patients and their families for their invaluable help, interest and
patience in this research.
Author Contributions
Conceptualization: RAH PD AH BWvB.
Data curation: RAH PD SvD BWvB.
Formal analysis: RAH PD CG BWvB.
Funding acquisition: RAH LF JAV BBADV SEF.
Investigation: RAH PD MSt JHF ABT ADe RS LAL HK UA EL MLU MA BGN EM LMAM
VBF DDGH KMdR AJS ASB HR JSC AF MSm TAG NDD CD AV CML ADu ER GA AB
CS JM AS BWvB.
Methodology: RAH PD SAG BWvB.
Project administration: SEF AH BWvB.
Resources: MSt SAG JHF ABT ADe RS LAL HK UA EL MLU MA BGN EM LMAM VBF
DDGH KMdR AJS ASB HR JSC AF MSm TAG NDD CD AV CML ADu ER GA AB CS JM
BBADV AS SEF BWvB.
Software: RAH CG SvD.
Supervision: PD LF JAV BBADV AS SEF AH BWvB.
Overlapping germline and somatic mutations in SETBP1
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006683 March 27, 2017 21 / 25
Validation: RAH PD BWvB.
Visualization: RAH BWvB.
Writing – original draft: RAH BWvB.
Writing – review & editing: RAH PD CG SvD JAV BBADV SEF AH BWvB.
References
1. Schinzel A, Giedion A. A syndrome of severe midface retraction, multiple skull anomalies, clubfeet, and
cardiac and renal malformations in sibs. Am J Med Genet. 1978; 1: 361–375. https://doi.org/10.1002/
ajmg.1320010402 PMID: 665725
2. Minn D, Christmann D, De Saint-Martin A, Alembik Y, Eliot M, Mack G, et al. Further clinical and senso-
rial delineation of Schinzel-Giedion syndrome: Report of two cases. Am J Med Genet. 2002; 109: 211–
217. https://doi.org/10.1002/ajmg.10348 PMID: 11977181
3. Al-Mudaffer M, Oley C, Price S, Hayes I, Stewart A, Hall CM, et al. Clinical and radiological findings in
Schinzel-Giedion syndrome. Eur J Pediatr. 2008; 167: 1399–1407. https://doi.org/10.1007/s00431-008-
0683-4 PMID: 18461363
4. Hoischen A, van Bon BWM, Gilissen C, Arts P, van Lier B, Steehouwer M, et al. De novo mutations of
SETBP1 cause Schinzel-Giedion syndrome. Nat Genet. 2010; 42: 483–485. https://doi.org/10.1038/ng.
581 PMID: 20436468
5. Piazza R, Valletta S, Winkelmann N, Redaelli S, Spinelli R, Pirola A, et al. Recurrent SETBP1 mutations
in atypical chronic myeloid leukemia. Nat Genet. 2012; 45: 18–24. https://doi.org/10.1038/ng.2495
PMID: 23222956
6. Sakaguchi H, Okuno Y, Muramatsu H, Yoshida K, Shiraishi Y, Takahashi M, et al. Exome sequencing
identifies secondary mutations of SETBP1 and JAK3 in juvenile myelomonocytic leukemia. Nat Genet.
2013; 45: 937–41. https://doi.org/10.1038/ng.2698 PMID: 23832011
7. Makishima H, Yoshida K, Nguyen N, Przychodzen B, Sanada M, Okuno Y, et al. Somatic SETBP1
mutations in myeloid malignancies. Nat Genet. 2013; 45: 942–6. https://doi.org/10.1038/ng.2696 PMID:
23832012
8. Hoischen A, Krumm N, Eichler EE. Prioritization of neurodevelopmental disease genes by discovery of
new mutations. Nat Neurosci. 2014; 17: 764–772. https://doi.org/10.1038/nn.3703 PMID: 24866042
9. Agha MM, Williams JI, Marrett L, To T, Zipursky A, Dodds L. Congenital abnormalities and childhood
cancer. Cancer. 2005; 103: 1939–1948. https://doi.org/10.1002/cncr.20985 PMID: 15770693
10. Bjorge T, Cnattingius S, Lie RT, Tretli S, Engeland A. Cancer Risk in Children with Birth Defects and in
Their Families: A Population Based Cohort Study of 5.2 Million Children from Norway and Sweden.
Cancer Epidemiol Biomarkers Prev. 2008; 17: 500–506. https://doi.org/10.1158/1055-9965.EPI-07-
2630 PMID: 18296646
11. Merks JHM, Ozgen HM, Koster J, Zwinderman AH, Caron HN, Hennekam RCM, et al. Prevalence and
Patterns of Morphological Abnormalities in Patients With Childhood Cancer. JAMA. 2008; 299: 61–69.
https://doi.org/10.1001/jama.2007.66 PMID: 18167407
12. Durmaz A, Durmaz B, Kadioglu B, Aksoylar S, Karapinar D, Koturoglu G, et al. The Association of minor
congenital anomalies and childhood cancer. Pediatr Blood Cancer. 2011; 56: 1098–102. https://doi.org/
10.1002/pbc.23049 PMID: 21360657
13. Kelleher FC, Fennelly D, Rafferty M. Common critical pathways in embryogenesis and cancer. Acta
Oncol (Madr). 2006; 45: 375–388.
14. Ravid T, Hochstrasser M. Diversity of degradation signals in the ubiquitin—proteasome system. Nat
Rev Mol Cell Biol. 2008; 9: 679–689. https://doi.org/10.1038/nrm2468 PMID: 18698327
15. Inoue D, Kitaura J, Matsui H, Hou H-A, Chou W-C, Nagamachi A, et al. SETBP1 mutations drive leuke-
mic transformation in ASXL1-mutated MDS. Leukemia. 2015; 29: 847–857. https://doi.org/10.1038/leu.
2014.301 PMID: 25306901
16. Cristobal I, Blanco FJ, Garcia-Orti L, Marcotegui N, Vicente C, Rifon J, et al. SETBP1 overexpression is
a novel leukemogenic mechanism that predicts adverse outcome in elderly patients with acute myeloid
leukemia. Blood. 2010; 115: 615–625. https://doi.org/10.1182/blood-2009-06-227363 PMID: 19965692
17. Oakley K, Han Y, Vishwakarma BA, Chu S, Bhatia R, Gudmundsson KO, et al. Setbp1 promotes the
self-renewal of murine myeloid progenitors via activation of Hoxa9 and Hoxa10. Blood. 2012; 119:
6099–6108. https://doi.org/10.1182/blood-2011-10-388710 PMID: 22566606
Overlapping germline and somatic mutations in SETBP1
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006683 March 27, 2017 22 / 25
18. Wu G, Xu G, Schulman BA, Jeffrey PD, Harper JW, Pavletich NP. Structure of a beta-TrCP1-Skp1-
beta-catenin complex: destruction motif binding and lysine specificity of the SCF(beta-TrCP1) ubiquitin
ligase. Mol Cell. 2003; 11: 1445–56. PMID: 12820959
19. Touge H, Fujinaga T, Okuda M, Aoshi H. Schinzel-Giedion syndrome. Int J Urol. 2001; 8: 237–241.
PMID: 11328425
20. Kondoh T, Kamimura N, Tsuru A, Matsumoto T, Matsuzaka T, Moriuchi H. A case of Schinzel-Giedion
syndrome complicated with progressive severe gingival hyperplasia and progressive brain atrophy.
Pediatr Int. 2001; 43: 181–184. PMID: 11285076
21. Carvalho E, Honjo R, Magalhães M, Yamamoto G, Rocha K, Naslavsky M, et al. Schinzel-Giedion syn-
drome in two Brazilian patients: Report of a novel mutation in SETBP1 and literature review of the clini-
cal features. Am J Med Genet Part A. 2015; 167: 1039–1046.
22. Suphapeetiporn K, Srichomthong C, Shotelersuk V. SETBP1 mutations in two Thai patients with Schin-
zel-Giedion syndrome. Clin Genet. 2011; 79: 391–393. https://doi.org/10.1111/j.1399-0004.2010.
01552.x PMID: 21371013
23. Lestner JM, Chong WK, Offiiah A, Kefas J, Vandersteen AM. Unusual neuroradiological features in
Schinzel-Giedion syndrome: a novel case. Clin Dysmorphol. 2012; 21: 152–4. https://doi.org/10.1097/
MCD.0b013e3283518f1e PMID: 22473152
24. Ko JM, Lim BC, Kim KJ, Hwang YS, Ryu HW, Lee JH, et al. Distinct neurological features in a patient
with Schinzel—Giedion syndrome caused by a recurrent SETBP1 mutation. Child’s Nerv Syst. 2013;
29: 525–529.
25. Miyake F, Kuroda Y, Naruto T, Ohashi I, Takano K, Kurosawa K. West Syndrome in a Patient With
Schinzel-Giedion Syndrome. J Child Neurol. 2015; 30: 932–936. https://doi.org/10.1177/
0883073814541468 PMID: 25028416
26. Lo´pez-Gonza´lez V, Domingo-Jime´nez MR, Burglen L, Ballesta-Martı´nez MJ, Whalen S, Piñero-Ferna´n-
dez JA, et al. [Schinzel-Giedion syndrome: a new mutation in SETBP1]. An Pediatr (Barc). 2015; 82:
e12–6.
27. Volk A, Conboy E, Wical B, Patterson M, Kirmani S. Whole-Exome Sequencing in the Clinic: Lessons
from Six Consecutive Cases from the Clinician’s Perspective. Mol Syndromol. 2015; 6: 23–31. https://
doi.org/10.1159/000371598 PMID: 25852444
28. Takeuchi A, Okamoto N, Fujinaga S, Morita H, Shimizu J, Akiyama T, et al. Progressive brain atrophy in
Schinzel—Giedion syndrome with a SETBP1 mutation. Eur J Med Genet. 2015; 58: 369–371. https://
doi.org/10.1016/j.ejmg.2015.05.006 PMID: 26096993
29. Herenger Y, Stoetzel C, Schaefer E, Scheidecker S, Manière M-C, Pelletier V, et al. Long term follow up
of two independent patients with Schinzel—Giedion carrying SETBP1 mutations. Eur J Med Genet.
2015; 58: 479–487. https://doi.org/10.1016/j.ejmg.2015.07.004 PMID: 26188272
30. Damm F, Itzykson R, Kosmider O, Droin N, Renneville a, Chesnais V, et al. SETBP1 mutations in 658
patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute mye-
loid leukemias. Leukemia. 2013; 27: 1401–3. https://doi.org/10.1038/leu.2013.35 PMID: 23443343
31. Laborde RR, Patnaik MM, Lasho TL, Finke CM, Hanson C a, Knudson R a, et al. SETBP1 mutations in
415 patients with primary myelofibrosis or chronic myelomonocytic leukemia: independent prognostic
impact in CMML. Leukemia. 2013; 27: 2100–2. https://doi.org/10.1038/leu.2013.97 PMID: 23558523
32. Pardanani a, Lasho TL, Laborde RR, Elliott M, Hanson C a, Knudson R a, et al. CSF3R T618I is a highly
prevalent and specific mutation in chronic neutrophilic leukemia. Leukemia. 2013; 27: 1870–1873.
https://doi.org/10.1038/leu.2013.122 PMID: 23604229
33. Meggendorfer M, Bacher U, Alpermann T, Haferlach C, Kern W, Gambacorti-Passerini C, et al.
SETBP1 mutations occur in 9% of MDS/MPN and in 4% of MPN cases and are strongly associated with
atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations. Leukemia. 2013;
27: 1852–1860. https://doi.org/10.1038/leu.2013.133 PMID: 23628959
34. Thol F, Suchanek KJ, Koenecke C, Stadler M, Platzbecker U, Thiede C, et al. SETBP1 mutation analy-
sis in 944 patients with MDS and AML. Leukemia. 2013; 27: 2072–2075. https://doi.org/10.1038/leu.
2013.145 PMID: 23648668
35. Fernandez-Mercado M, Pellagatti A, Di Genua C, Larrayoz MJ, Winkelmann N, Aranaz P, et al. Muta-
tions in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic mark-
ers associated with disease progression. Br J Haematol. 2013; 163: 235–9. https://doi.org/10.1111/bjh.
12491 PMID: 23889083
36. Shiba N, Ohki K, Park M, Sotomatsu M, Kudo K, Ito E, et al. SETBP1 mutations in juvenile myelomono-
cytic leukaemia and myelodysplastic syndrome but not in paediatric acute myeloid leukaemia. Br J Hae-
matol. 2014; 164: 156–159. https://doi.org/10.1111/bjh.12595 PMID: 24117422
Overlapping germline and somatic mutations in SETBP1
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006683 March 27, 2017 23 / 25
37. Hou H-AA, Kuo Y-YY, Tang J-LL, Chou W-CC, Yao M, Lai Y-JJ, et al. Clinical implications of the
SETBP1 mutation in patients with primary myelodysplastic syndrome and its stability during disease
progression. Am J Hematol. 2014; 89: 181–6. https://doi.org/10.1002/ajh.23611 PMID: 24127063
38. Lasho TL, Mims a, Elliott M a, Finke C, Pardanani a, Tefferi a. Chronic neutrophilic leukemia with con-
current CSF3R and SETBP1 mutations: single colony clonality studies, in vitro sensitivity to JAK inhibi-
tors and lack of treatment response to ruxolitinib. Leukemia. 2014; 1: 1–3.
39. Senı´n A, Arenillas L, Martı´nez-Avile´s L, Ferna´ndez-Rodrı´guez C, Bellosillo B, Florensa L, et al. [Molecu-
lar characterization of atypical chronic myeloid leukemia and chronic neutrophilic leukemia]. Med Clin
(Barc). 2015; 144: 487–90.
40. Fabiani E, Falconi G, Fianchi L, Criscuolo M, Leone G, Voso MT. SETBP1 mutations in 106 patients
with therapy-related myeloid neoplasms. Haematologica. 2014; 99: e152–e153. https://doi.org/10.
3324/haematol.2014.108159 PMID: 24907359
41. Ammatuna E, Eefting M, van Lom K, Kavelaars FF, Valk PJM, Touw IP. Atypical chronic myeloid leuke-
mia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxoliti-
nib. Ann Hematol. 2015; 94: 879–880. https://doi.org/10.1007/s00277-014-2272-0 PMID: 25491280
42. Elliott MA, Pardanani A, Hanson CA, Lasho TL, Finke CM, Belachew AA, et al. ASXL1 mutations are
frequent and prognostically detrimental in CSF3R-mutated chronic neutrophilic leukemia. Am J Hema-
tol. 2015; 90: 653–656. https://doi.org/10.1002/ajh.24031 PMID: 25850813
43. Cui Y, Li B, Gale RP, Jiang Q, Xu Z, Qin T, et al. CSF3R, SETBP1 and CALR mutations in chronic neu-
trophilic leukemia. J Hematol Oncol. 2014; 7: 77. https://doi.org/10.1186/s13045-014-0077-1 PMID:
25316523
44. Gambacorti-Passerini CB, Donadoni C, Parmiani A, Pirola A, Redaelli S, Signore G, et al. Recurrent
ETNK1 mutations in atypical chronic myeloid leukemia. Blood. 2015; 125: 499–503. https://doi.org/10.
1182/blood-2014-06-579466 PMID: 25343957
45. Bartels S, Lehmann U, Bu¨sche G, Schlue J, Hussein K, Debatin D, et al. De novo CSF3R mutation
associated with transformation of myeloproliferative neoplasm to atypical CML. Ann Hematol. 2015; 94:
1255–1256. https://doi.org/10.1007/s00277-015-2366-3 PMID: 25865944
46. Maxson JE, Luty SB, MacManiman JD, Paik JC, Gotlib J, Greenberg P, et al. The Colony-Stimulating
Factor 3 Receptor T640N Mutation Is Oncogenic, Sensitive to JAK Inhibition, and Mimics T618I. Clin
Cancer Res. 2016; 22: 757–764. https://doi.org/10.1158/1078-0432.CCR-14-3100 PMID: 26475333
47. Lasho TL, Elliott MA, Pardanani A, Tefferi A. CALR mutation studies in chronic neutrophilic leukemia.
Am J Hematol. 2014; 89: 450.
48. Xu L, Gu Z-H, Li Y, Zhang J-L, Chang C-K, Pan C-M, et al. Genomic landscape of CD34+ hematopoietic
cells in myelodysplastic syndrome and gene mutation profiles as prognostic markers. Proc Natl Acad
Sci U S A. 2014; 111: 8589–94. https://doi.org/10.1073/pnas.1407688111 PMID: 24850867
49. Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data
with DESeq2. Genome Biol. 2014; 15: 550. https://doi.org/10.1186/s13059-014-0550-8 PMID:
25516281
50. Subramanian A, Subramanian A, Tamayo P, Tamayo P, Mootha VK, Mootha VK, et al. Gene set enrich-
ment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc
Natl Acad Sci U S A. 2005;
51. Lehman AM, McFadden D, Pugash D, Sangha K, Gibson WT, Patel MS. Schinzel-Giedion syndrome:
Report of splenopancreatic fusion and proposed diagnostic criteria. Am J Med Genet Part A. 2008; 146:
1299–1306.
52. Filges I, Shimojima K, Okamoto N, Rothlisberger B, Weber P, Huber AR, et al. Reduced expression by
SETBP1 haploinsufficiency causes developmental and expressive language delay indicating a pheno-
type distinct from Schinzel-Giedion syndrome. J Med Genet. 2011; 48: 117–122. https://doi.org/10.
1136/jmg.2010.084582 PMID: 21037274
53. Barnett CP, van Bon BWM. Monogenic and chromosomal causes of isolated speech and language
impairment. J Med Genet. 2015; 52: 719–29. https://doi.org/10.1136/jmedgenet-2015-103161 PMID:
26139234
54. Kratz CP, Niemeyer CM, Castleberry RP, Cetin M, Bergstra¨sser E, Emanuel PD, et al. The mutational
spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative
disease. Blood. 2005; 106: 2183–5. https://doi.org/10.1182/blood-2005-02-0531 PMID: 15928039
55. Tartaglia M, Martinelli S, Stella L, Bocchinfuso G, Flex E, Cordeddu V, et al. Diversity and functional
consequences of germline and somatic PTPN11 mutations in human disease. Am J Hum Genet. 2006;
78: 279–90. https://doi.org/10.1086/499925 PMID: 16358218
56. Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev
Cancer. 2007;
Overlapping germline and somatic mutations in SETBP1
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006683 March 27, 2017 24 / 25
57. Hoischen A, van Bon BWM, Rodrı´guez-Santiago B, Gilissen C, Vissers LELM, de Vries P, et al. De
novo nonsense mutations in ASXL1 cause Bohring-Opitz syndrome. Nat Genet. 2011; 43: 729–731.
https://doi.org/10.1038/ng.868 PMID: 21706002
58. Tsurusaki Y, Okamoto N, Ohashi H, Kosho T, Imai Y, Hibi-Ko Y, et al. Mutations affecting components
of the SWI/SNF complex cause Coffin-Siris syndrome. Nat Genet. 2012; 44: 376–378. https://doi.org/
10.1038/ng.2219 PMID: 22426308
59. Gibson WT, Hood RL, Zhan SH, Bulman DE, Fejes AP, Moore R, et al. Mutations in EZH2 Cause
Weaver Syndrome. Am J Hum Genet. 2012; 90: 110–118. https://doi.org/10.1016/j.ajhg.2011.11.018
PMID: 22177091
60. Genovese G, Ka¨hler AK, Handsaker RE, Lindberg J, Rose SA, Bakhoum SF, et al. Clonal Hematopoie-
sis and Blood-Cancer Risk Inferred from Blood DNA Sequence. N Engl J Med. 2014; 371: 2477–2487.
https://doi.org/10.1056/NEJMoa1409405 PMID: 25426838
61. McKerrell T, Park N, Moreno T, Grove CSS, Ponstingl H, Stephens J, et al. Leukemia-Associated
Somatic Mutations Drive Distinct Patterns of Age-Related Clonal Hemopoiesis. Cell Rep. 2015; 10:
1239–1245. https://doi.org/10.1016/j.celrep.2015.02.005 PMID: 25732814
62. Mason CC, Khorashad JS, Tantravahi SK, Kelley TW, Zabriskie MS, Yan D, et al. Age-related muta-
tions and chronic myelomonocytic leukemia. Leukemia. 2015;
63. Bjornsson HT, Benjamin JS, Zhang L, Weissman J, Gerber EE, Chen Y-C, et al. Histone deacetylase
inhibition rescues structural and functional brain deficits in a mouse model of Kabuki syndrome. Sci
Transl Med. 2014; 6: 256ra135–256ra135. https://doi.org/10.1126/scitranslmed.3009278 PMID:
25273096
64. Neviani P, Perrotti D. SETting OP449 into the PP2A-activating drug family. Clin Cancer Res. 2014; 20:
2026–2028. https://doi.org/10.1158/1078-0432.CCR-14-0166 PMID: 24634375
65. Agarwal A, Meckenzie RJ, Pippa R, Eide CA, Oddo J, Tyner JW, Sears R, et al. OP449, a Novel SET
Antagonist, Is Cytotoxic To Leukemia Cells and Enhances Efficacy Of Tyrosine Kinase Inhibitors In
Drug-Resistant Myeloid Leukemias. Blood. 2013; 122: 2511 LP-2511.
66. Perrotti D, Neviani P. Protein phosphatase 2A: A target for anticancer therapy. Lancet Oncol. Elsevier
Ltd; 2013; 14: e229–e238.
67. Deriziotis P, O’Roak BJ, Graham SA, Estruch SB, Dimitropoulou D, Bernier RA, et al. De novo TBR1
mutations in sporadic autism disrupt protein functions. Nat Commun. 2014; 5: 4954. https://doi.org/10.
1038/ncomms5954 PMID: 25232744
68. Van Durme J, Delgado J, Stricher F, Serrano L, Schymkowitz J, Rousseau F. A graphical interface for
the FoldX forcefield. Bioinformatics. 2011; 27: 1711–1712. https://doi.org/10.1093/bioinformatics/
btr254 PMID: 21505037
69. Gilissen C, Hehir-Kwa JY, Thung DT, van de Vorst M, van Bon BWM, Willemsen MH, et al. Genome
sequencing identifies major causes of severe intellectual disability. Nature. 2014; 511: 344–347. https://
doi.org/10.1038/nature13394 PMID: 24896178
Overlapping germline and somatic mutations in SETBP1
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1006683 March 27, 2017 25 / 25
